TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27760084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional treatment alone)
Study: 25925031
Drug: Opioid-free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free anesthesia with dexmedetomidine, lidocaine, and propofol infusions (Group DL)
Study: 25925031
Drug: Opioid-based anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-based anesthesia with remifentanil and propofol infusions (Group RF)
Study: 23921331
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 6 lumbar facet joints with triamcinolone hexacetonide
Study: 23921331
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of triamcinolone acetonide at 6 lumbar paravertebral points
Study: 19384786
Drug: Avastin (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avastin (1.25 mg in 0.05 mL) every six weeks
Study: 19384786
Drug: Lucentis (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucentis (0.05 mg in 0.05 mL) every four weeks
Study: 11431744
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU IFN-alpha2b 3 times a week plus ribavirin 1,000 mg/d for 12 months
Study: 790129
Drug: Bencyclan (Fludilat)
Normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclan (Fludilat) administered intravenously at a dosage of 500 mg per day
Study: 30545448
Drug: Incremental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental treatment (pre‐procedural cefazolin plus vancomycin, intraprocedural bacitracin pocket wash, and 2‐day post‐procedural oral cephalexin)
Study: 30545448
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (pre‐procedural cefazolin infusion)
Study: 30545448
Drug: Incremental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental treatment
Study: 24124893
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise intervention (12 weeks, twice weekly, cardiovascular and strength training, relaxation)
Study: 15830221
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg alprazolam
Study: 9700978
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alprazolam
Study: 8467286
Drug: rhGM‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF alone (concurrent control)
Study: 3938925
Drug: Metrifonate treatment
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate treatment (MIT)
Study: 21078465
Drug: SBIRT (Screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT (Screening, Brief Intervention, and Referral to Treatment) by emergency nurses
Study: 16863482
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, without food (treatment A)
Study: 16863482
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg on the evening before and 150 mg on the day of study drug administration, with food (treatment B)
Study: 16863482
Drug: Food alone
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food alone (treatment C, control)
Study: 14644860
Drug: Oral pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pilocarpine (5 mg twice a day)
Study: 11007680
Drug: 200 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/wk of intravenous iron dextran (IVID) for 5 weeks
Study: 11007680
Drug: 500 mg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/wk of intravenous iron dextran (IVID) for 2 weeks
Study: 1728443
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Study: 1728443
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with intravenous isosorbide dinitrate (ISDN; 5 mg/hr)
Study: 2877386
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg a day)
Study: 2877386
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg a day)
Study: 29546560
Drug: Laparoscopic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic low anterior resection (L-LAR)
Study: 27097042
Drug: Carbohydrate-Protein (CHO-P;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-Protein (CHO-P; 0.8 g carbohydrate·kg body mass [BM-1]·h-1 plus 0.4 g protein·kg BM-1·h-1)
Study: 27097042
Drug: Isocaloric Carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric Carbohydrate (CHO; 1.2 g carbohydrate·kg BM-1·h-1)
Study: 20636196
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) group
Study: 19365011
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg pegaptanib sodium
Study: 19365011
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg pegaptanib sodium
Study: 12511360
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% unpreserved eyedrops (0.5 ml)
Study: 10190222
Drug: Olanzapine therapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine therapy
Study: 10190222
Drug: Haloperidol therapy
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol therapy
Study: 8926734
Drug: Passive inhalation
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive inhalation of 100 and 200 mg freebase cocaine
Study: 8926734
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 1 mg cocaine hydrochloride
Study: 2257862
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of low-dose prednisolone (0.3-0.6 mg/kg body weight)
Study: 25966065
Drug: Intracoronary transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary transplantation of umbilical cord MSCs along with medication
Study: 25966065
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (control group)
Study: 27606973
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) treatment
Study: 19228659
Drug: Combination ETN
Normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ETN and MTX treatment
Study: 10673065
Drug: Niravoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niravoline (0.5 to 2 mg iv)
Study: 10673065
Drug: Niravoline (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niravoline (1.5 mg or 2 mg iv)
Study: 7667331
Drug: 5-HT1A agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT1A agonist ipsapirone (IPS)
Study: 8452380
Drug: SDI test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDI test with adjuvant chemotherapy using tegafur and one of the following drugs: mitomycin C (MMC), adriamycin (ADM), or cisplatin (CDDP).
Study: 3526915
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy procedure (NDT)
Study: 18034788
Drug: SSP+ (platelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSP+ (platelet additive solution with potassium and magnesium)
Study: 18034788
Drug: Intersol (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intersol (control platelet additive solution)
Study: 10512132
Drug: Oral etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral etoposide, 50 mg/m2, days 1‐21
Study: 10512132
Drug: Intravenous etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous etoposide, 200 mg/m2, days 1‐3
Study: 2037844
Drug: Caffeine doses
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine doses (four different doses administered)
Study: 20089780
Drug: Whole-grain rye
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain rye bread (minimum 240 g/d)
Study: 15629602
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MC) 15 mg/M(2)
Study: 15629602
Drug: Porfiromycin (POR)
Normalized name: Porfiromycin
DrugBank: Porfiromycin (DB06478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porfiromycin (POR) 40 mg/M(2)
Study: 12183719
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation program (15 minutes of stimulation of oral structures, once per day for 10 days)
Study: 29793053
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with sodium (0.8 g/d) and fluid (800 mL/d) restriction
Study: 27003301
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of Lupron
Study: 27003301
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of Lupron and estrogen replacement
Study: 10995594
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion at 100 mg/kg for 30 min
Study: 10995594
Drug: D-arginine infusion
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D-arginine infusion at 100 mg/kg for 30 min
Study: 10995594
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion at 500 mg/kg for 30 min
Study: 10995594
Drug: D-arginine infusion
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D-arginine infusion at 500 mg/kg for 30 min
Study: 11799078
Drug: D-arginine infusion
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D-arginine infusion
Study: 9315539
Drug: Enalapril (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.2 to 0.3 mg x kg[-1] x d[-1], maximum 15 mg) for 10 weeks
Study: 3511311
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy (N = 11)
Study: 3511311
Drug: Intensive conventional
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive conventional insulin therapy (N = 11)
Study: 18180980
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser treatment (10.6 microm and 650 nm laser irradiation)
Study: 18180980
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment (sham laser treatment)
Study: 12488380
Drug: i.v. amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. amino acid infusion (4 kJ kg(‐1) h(‐1) starting 2 h before surgery)
Study: 12488380
Drug: i.v. amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. amino acid infusion
Study: 11332875
Drug: Rimantadine hydrochloride
Normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rimantadine hydrochloride (100 mg) - Test formulation (Rimantadin Lachema)
Study: 9153484
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy for 1 week (n = 25)
Study: 9153484
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy for 2 weeks (n = 25)
Study: 7968650
Drug: HRT (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (oral or transdermal)
Study: 7968650
Drug: HRT (transdermal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (transdermal)
Study: 7968650
Drug: HRT (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (oral)
Study: 3478732
Drug: 3mg vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg vaginal tablet (Upjohn)
Study: 28288767
Drug: IVM oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVM oral paste (0.2 mg/kg)
Study: 28288767
Drug: IVM oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVM oral solution (0.2 mg/kg)
Study: 28288767
Drug: IVM IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVM IM solution (0.2 mg/kg)
Study: 27366506
Drug: Deep breathing
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep breathing exercises, respiratory physiotherapy and O2 therapy
Study: 29549175
Drug: Abatacept 3
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept 3 mg/kg
Study: 29549175
Drug: Abatacept 10
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept 10 mg/kg
Study: 21128258
Drug: Abatacept 30/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept 30/10 mg/kg
Study: 10429772
Drug: Dolasetron (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (12.5 mg)
Study: 8779383
Drug: Test device
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test device comprising a Tuohy needle and clamp weighing 75.02 g applied to five vein sites (dorsum of arm, dorsum of hand, cephalic, ventrum of arm, cubital fossa)
Study: 1649838
Drug: Ovine CRH
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine CRH infusion (1 microgram/kg.h)
Study: 6304787
Drug: Rolipram (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolipram (3 mg per day)
Study: 30975204
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement oral appliance (OAm) with embedded thermosensitive microchip
Study: 30975204
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement oral appliance (OAm)
Study: 29480527
Drug: Internet-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based training with weekly phone calls (n=232)
Study: 27899456
Drug: Inhalation routes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation routes (smoked and vaporized)
Study: 27899456
Drug: Oral dosing
Normalized name: oral dosing devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosing
Study: 27899456
Drug: Combined THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined THC ≥5 μg/L plus THCCOOH/11‐hydroxy‐THC ratio <20 cutoff
Study: 24670413
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II receptor blocker)
Study: 20065047
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B daily regimen (1 mg kg(‐1) day(‐1) for 15 days)
Study: 20065047
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B alternate day regimen (1 mg kg(‐1) on alternate days for 15 days)
Study: 7565822
Drug: Rectal solution
Normalized name: Rectal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal solution of apomorphine (10 or 15 mg)
Study: 7565822
Drug: Gelatin suppository
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin suppository (25 and 50 mg)
Study: 7565822
Drug: Witepsol‐H15 suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Witepsol‐H15 suppository (50 and 100 mg)
Study: 2225702
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg daily for 2 weeks
Study: 2225702
Drug: Indomethacin, 50
Normalized name: Indomethacin, 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 50 mg twice a day
Study: 30643982
Drug: SK-1202 (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-1202 (26 g/day)
Study: 30643982
Drug: SK-1202 (39
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-1202 (39 g/day)
Study: 28025352
Drug: Bupivacaine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5 ml; 5 mg/ml)
Study: 23743535
Drug: Loading (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading (LD group) - 3 mandatory doses of intravitreal bevacizumab
Study: 23743535
Drug: No Loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Loading (NLD group) - no mandatory doses after baseline dose
Study: 18940534
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (10, 20, or 40 mg/day) for 6 weeks
Study: 18940534
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (40 mg/day) for 33 weeks
Study: 18940534
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (10 or 20 mg/day) for 53 weeks
Study: 19526755
Drug: Astragalus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus Injection (AI)
Study: 12480116
Drug: Coaching by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching by community pharmacists (3 drug coaching contacts and a 25-min take-home video)
Study: 31721495
Drug: Conventional immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate implant placement
Study: 29224641
Drug: Individualized feedback
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized feedback on adherence to prescribing evidence-based therapy for physicians; weekly home visits from community health workers for patients.
Study: 29224641
Drug: Regular updates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular updates on advances in HF management for physicians; monthly HF educational tip sheets for patients.
Study: 22565162
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l Golytely single‐dosed (Go‐Si)
Study: 22565162
Drug: 4 l
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 l Golytely split‐dosed (Go‐Sp)
Study: 22565162
Drug: 238 g
Normalized name: AVOBENZONE 3.371 g in 112.38 g / OXYBENZONE 6.743 g in 112.38 g / OCTINOXATE 8.429 g in 112.38 g / HOMOSALATE 11.238 g in 112.38 g / OCTISALATE 5.619 g in 112.38 g TOPICAL CREAM [Advanced Sun Resistance SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 238 g MiraLAX in 64 oz of Gatorade single‐dosed (Mlax‐Si)
Study: 17438555
Drug: Family-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based group treatment (15 separate sessions for parents and children)
Study: 15960271
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg/ml with 6 microg/kg naloxone
Study: 15960271
Drug: 0.4 mg/ml
Normalized name: thymol 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/ml morphine
Study: 11922881
Drug: Indoleamine (via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoleamine (via tryptophan depletion) plus catecholamine (via alpha‐methyl‐paratyrosine administration) depletion
Study: 11922881
Drug: Indoleamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoleamine plus sham (via diphenhydramine administration) catecholamine depletion
Study: 9704689
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor ramipril (2.5 to 20 mg/day)
Study: 26349548
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of RV1 and OPV (monovalent, bivalent, or trivalent)
Study: 26349548
Drug: Staggered administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Staggered administration of RV1 and OPV (≥1 day apart)
Study: 23349519
Drug: Levodopa (6.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (6.65 ± 1.66 mg/kg/d)
Study: 17522235
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal and polychemotherapy therapy
Study: 15203440
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g naltrexone implant
Study: 15203440
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g naltrexone implant
Study: 12376047
Drug: Laser light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser light treatment (wavelength 810 nm, dose 4 J/cm2) in Group A
Study: 12376047
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (quasi-laser therapy) in Group B
Study: 1971199
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 IV lidocaine administered 1-4 minutes before intubation
Study: 6771829
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg methylphenidate
Study: 24034834
Drug: 16 G
Normalized name: Maltsupex, 16 g/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 G biopsy needles (Group A)
Study: 24034834
Drug: 18 G
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 G biopsy needles (Group B)
Study: 2452997
Drug: Midodrine (alpha-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (alpha-adrenergic agonist)